Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX) has received a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $15.14.

A number of research firms recently commented on CATX. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Monday, January 13th. UBS Group began coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Finally, Oppenheimer reduced their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $3.63 on Friday. The stock’s 50-day simple moving average is $3.87 and its 200-day simple moving average is $9.85. Perspective Therapeutics has a 52 week low of $2.70 and a 52 week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Research analysts predict that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Activity

In other Perspective Therapeutics news, CEO Johan M. Spoor bought 8,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average price of $3.77 per share, with a total value of $30,160.00. Following the completion of the purchase, the chief executive officer now owns 36,257 shares in the company, valued at $136,688.89. This represents a 28.31 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Heidi Henson bought 25,975 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were acquired at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the purchase, the director now owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Koa Wealth Management LLC bought a new position in Perspective Therapeutics in the fourth quarter worth approximately $83,000. Wealth Effects LLC grew its stake in Perspective Therapeutics by 186.8% in the fourth quarter. Wealth Effects LLC now owns 38,000 shares of the company’s stock worth $121,000 after purchasing an additional 24,750 shares in the last quarter. SG Americas Securities LLC grew its stake in Perspective Therapeutics by 41.3% in the fourth quarter. SG Americas Securities LLC now owns 26,088 shares of the company’s stock worth $83,000 after purchasing an additional 7,627 shares in the last quarter. Trueblood Wealth Management LLC lifted its holdings in Perspective Therapeutics by 37.0% during the fourth quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock worth $71,000 after buying an additional 6,000 shares during the period. Finally, Taylor & Morgan Wealth Management LLC lifted its holdings in Perspective Therapeutics by 86.7% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 56,000 shares of the company’s stock worth $179,000 after buying an additional 26,000 shares during the period. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.